HK Movers | Hengrui Pharma Surges over 7% After Striking Global Strategic Collaboration and Licensing Agreement with Bristol-Myers Squibb Company

Tiger Newspress05-12

Hengrui Pharma announced at noon that it had entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company, under which it may receive related payments of up to USD950 million.

The stock surged in the afternoon session, last trading at HKD71.1, up 7.65%.

The group announced that it has reached a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company to jointly advance 13 early-stage programs spanning oncology, hematology and immunology.

Under the agreement, Bristol-Myers Squibb Company will pay HENGRUI PHARMA up to USD950 million, including an upfront payment of USD600 million, a first anniversary payment of USD175 million, and a second conditional anniversary payment of USD175 million in 2028. The total potential deal value could reach approximately USD15.2 billion, including the exercise of options for co-development programs and the achievement of development, regulatory and commercialization milestones for all programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107969754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 13:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107969754","market":"hk","top_or_hot":-1,"title":"HK Movers | Hengrui Pharma Surges over 7% After Striking Global Strategic Collaboration and Licensing Agreement with Bristol-Myers Squibb Company","media":"Tiger Newspress","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01276\">Hengrui Pharma</a> announced at noon that it had entered into a global strategic collaboration and licensing agreement with <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb Company</a>, under which it may receive related payments of up to USD950 million. </p><p>The stock surged in the afternoon session, last trading at HKD71.1, up 7.65%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ebca3580664617bada1eb8580ab10331\" tg-width=\"408\" tg-height=\"126\"/></p><p>The group announced that it has reached a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company to jointly advance 13 early-stage programs spanning oncology, hematology and immunology. </p><p>Under the agreement, Bristol-Myers Squibb Company will pay HENGRUI PHARMA up to USD950 million, including an upfront payment of USD600 million, a first anniversary payment of USD175 million, and a second conditional anniversary payment of USD175 million in 2028. The total potential deal value could reach approximately USD15.2 billion, including the exercise of options for co-development programs and the achievement of development, regulatory and commercialization milestones for all programs.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | Hengrui Pharma Surges over 7% After Striking Global Strategic Collaboration and Licensing Agreement with Bristol-Myers Squibb Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | Hengrui Pharma Surges over 7% After Striking Global Strategic Collaboration and Licensing Agreement with Bristol-Myers Squibb Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-05-12 13:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/01276\">Hengrui Pharma</a> announced at noon that it had entered into a global strategic collaboration and licensing agreement with <a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb Company</a>, under which it may receive related payments of up to USD950 million. </p><p>The stock surged in the afternoon session, last trading at HKD71.1, up 7.65%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ebca3580664617bada1eb8580ab10331\" tg-width=\"408\" tg-height=\"126\"/></p><p>The group announced that it has reached a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company to jointly advance 13 early-stage programs spanning oncology, hematology and immunology. </p><p>Under the agreement, Bristol-Myers Squibb Company will pay HENGRUI PHARMA up to USD950 million, including an upfront payment of USD600 million, a first anniversary payment of USD175 million, and a second conditional anniversary payment of USD175 million in 2028. The total potential deal value could reach approximately USD15.2 billion, including the exercise of options for co-development programs and the achievement of development, regulatory and commercialization milestones for all programs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1107969754","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107969754","pubTimestamp":1778563133,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"$Hengrui Pharma(01276)$ announced at noon that it had entered into a global strategic collaboration and licensing agreement with $Bristol-Myers Squibb Company(BMY)$, under which it may receive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药","BMY":"施贵宝"},"translate_title":"HK Movers|恒瑞医药与百时美施贵宝公司达成全球战略合作及授权协议后大涨超7%","themeId":"330240692f324d079ccf839d9e4180bf","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/5356beb1b39bf250dbbc9889fe3b11a8","symbols_score_info":{"BMY":2,"01276":2},"content_text":"Hengrui Pharma announced at noon that it had entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company, under which it may receive related payments of up to USD950 million. The stock surged in the afternoon session, last trading at HKD71.1, up 7.65%.The group announced that it has reached a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company to jointly advance 13 early-stage programs spanning oncology, hematology and immunology. Under the agreement, Bristol-Myers Squibb Company will pay HENGRUI PHARMA up to USD950 million, including an upfront payment of USD600 million, a first anniversary payment of USD175 million, and a second conditional anniversary payment of USD175 million in 2028. The total potential deal value could reach approximately USD15.2 billion, including the exercise of options for co-development programs and the achievement of development, regulatory and commercialization milestones for all programs.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107969754","isCrawlerRequest":true}